On Dec. 5, 2023, Benefits Canada held its annual Face to Face Drug Plan Management Forum, the industry’s most popular drug benefits conference.
Industry experts presented a full day of educational sessions, which informed attendees about fresh drug plan design insights, key trends and considerations.
Here’s what you missed!
Dr. Shereen Ezzat
University Health Network
Many plan members with diabetes struggle with adherence to daily insulin injections and research has found the majority of patients wish they could achieve the same control over their condition with fewer injections.
This session was made possible by Boehringer-Ingelheim Canada, Merck Canada Inc. and Novo Nordisk.
Innovative Medicines Canada
A recent survey by Innovative Medicines Canada found there are growing listing delays among Canada’s private drug plans.
Health Solutions by Shoppers
Pharmacists are now uniquely positioned to support Canadians at a time when the public health-care system is stretched thin, creating significant barriers for people looking to access care.
Sun Life Financial
Medavie Blue Cross
With chronic conditions growing in prevalence among plan members, plan sponsors have their work cut out for them in designing benefits plans that provide adequate health support and employee satisfaction while also being cost effective.
Express Scripts Canada
While medications for three interconnected chronic conditions — cardiovascular disease, diabetes and obesity — represent a growing proportion of employers’ drug spend, there’s plenty that can be done to help employees’ slow the progression of these conditions while managing drug plan costs.
Canadian Biosimilars Forum
Despite the safety and efficacy of biosimilars — and the potential cost savings they offer — uptake among private payers has been low historically and is only starting to gain steam.
Best Medicines Coalition
Plan sponsors, private payers can work together to help employees with rare diseases access novel treatments
It’s important for private payers and employers to be nimble and innovative to support plan members seeking access to novel drugs and treatments by addressing common hurdles within their own drug plans.